Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The 2025 National Medical Insurance and Commercial Health Insurance Innovation Drug Catalogs were released, adding 114 new drugs to the national insurance list, with a success rate of 88%, significantly higher than the previous year's 76% [2] - The first three quarters of 2025 saw a notable recovery in domestic innovative drug financing, with 324 financing events totaling $5.51 billion, a 67.6% increase year-on-year [3] - The flu positivity rate has not peaked yet, with a significant increase in flu cases, indicating a growing market for flu medications [4] - The report highlights breakthroughs in dual-target and new-target opportunities in the autoimmune field, with several companies making significant advancements [5] - There is a focus on inhalation formulations in respiratory diseases, with new drugs showing promising results [6] - Progress in liver-targeted small nucleic acids is noted, with companies like Arrowhead Pharmaceuticals making strides in this area [7] Summary by Sections 1. National Medical Insurance and Commercial Insurance Innovation Drug Catalogs - The 2025 catalog added 114 new drugs, including 50 innovative drugs, with a success rate of 88% [2] 2. Financing Trends and CXO Order Changes - Innovative drug financing events increased by 5.2% year-on-year, with total financing amounting to $5.51 billion [3] 3. Flu Positivity Rates - The flu positivity rate reached 51.1%, indicating a rising demand for flu medications [4] 4. Autoimmune Field Developments - Significant partnerships and advancements in dual-target drugs for autoimmune diseases were reported [5] 5. Inhalation Formulations in Respiratory Diseases - New inhalation drugs are showing positive clinical results, indicating a shift in treatment approaches [6] 6. Progress in Liver-Targeted Small Nucleic Acids - Arrowhead Pharmaceuticals achieved a milestone payment for its innovative RNA therapy, expanding its research pipeline [7] 7. Stock Recommendations - The report recommends stocks in various sectors, including inhalation formulations, small nucleic acids, and innovative drugs, highlighting specific companies for investment [8]

Core Viewpoint - The pharmaceutical and biotechnology market currently lacks a clear main theme, but the release of the first "Medical Insurance + Commercial Insurance Dual Directory" by the National Healthcare Security Administration on December 7 may boost investment enthusiasm for innovative drugs [1] Market Performance - Last week, the pharmaceutical and biotechnology sector had a return of -0.74%, underperforming the CSI 300 by 2.02%, ranking 21st among 31 primary sub-industry indices [2] - The pharmaceutical commercial sub-sector had the highest weekly return at 5.19%, outperforming the CSI 300 by 3.91%, while the medical services sub-sector ranked sixth with a return of -1.37%, underperforming the CSI 300 by 2.65% [2] Innovative Drugs - Companies recommended for investment in innovative drugs include: - Innovent Biologics - 3SBio - Hengrui Medicine - Kelun-Biotech - Baillie Gifford - Rongchang Biologics - Yimeng Biologics - Huyou Pharmaceutical - King’s Ray Biotech - Valiant Biotech - Lee's Pharmaceutical [2] CXO and Life Sciences Upstream Industry Chain - Recommended global CXO leaders include: - WuXi AppTec - WuXi Biologics - WuXi AppTec's subsidiary - Kanglong Chemical - Kailai Ying [3] - Recommended domestic clinical CRO leaders include: - Tigermed - Proprius - Nossg - Sunshine Nuohe [3] - Recommended resource-type CXOs include: - Zhaoyan New Drug - Yinos - Medicy - Baiaosaitu - Yaokang Biotech [3] - Recommended companies in the life sciences upstream industry chain include: - Baipusais - Haoyuan Pharmaceutical - Bid Pharmaceutical - Nami Technology - Aopumai - Haier Biomedical - Aladdin - Titan Technology [3] Companies with Improved Operations and High Dividends - Companies recommended for attention include: - Baiyunshan - Sinopharm [4] High-end Medical Equipment - Recommended companies benefiting from overseas pharmaceutical investments include: - Sensong International - Dongfulong - Chutian Technology [4] - Companies expected to see business growth from hospital procurement recovery include: - United Imaging - Kaili Medical - Xinhua Medical - Mindray Medical - Aohua Endoscopy - Mountain Outside Mountain [4] - Companies with domestic demand-driven medical device recovery include: - Yiyue Medical - Kefu Medical - Sanofi Biotech [4] - Companies with restored overseas orders include: - Meihua Medical - Haitai New Light - Ruimaite [4] - Companies with increasing market penetration in high-end medical consumables include: - Xinmai Medical - Micron Medical - Weigao - Micron Brain Science - Aikang Medical - Chunli Medical [4]

"视觉重建是脑机接口技术临床转化的一个优质场景，其特点是临床需求迫切、临床终点明确。"陈文凯 表示。他还具体阐释了系统的工作原理："我们的视觉重建系统，创新性地融合了虚拟现实（VR）与脑 机双学习闭环大规模电极刺激。通过植入体内的'RV-IPG'刺激模块与外部'VPU'处理单元协同工作，能 记者 宋薇萍 摄 ◎记者 宋薇萍 近日，在我国首个脑机接口未来产业集聚区——"脑智天地"举行的2025年脑机接口大会上，相关企业纷 纷携新产品、新技术亮相。大会通过全国脑机接口竞技赛、颠覆性技术创新大赛等活动，强化优质项目 发现和加速培育机制，为推进脑机接口前沿技术创新与未来产业发展营造了良好创新环境。 上海市人民政府副秘书长夏科家在致辞时表示，面向未来，上海将持续推动脑机接口前沿技术创新和未 来产业培育。强化高风险高价值基础研究和颠覆性技术创新，推动脑机接口在医疗、教育、工业等更多 领域落地生根。优化完善产业创新生态建设，培育更多具有国际竞争力的企业团队，深化国际交流与合 作，共同推动脑机接口未来产业发展。 企业秀"脑力" 2025脑机接口大会俨然成了企业的"秀场"。 在会场内的核心发布环节，阶梯医疗、景昱医疗、智冉科技 ...

12月5日的资金流向数据方面，主力资金净流出933.9万元，占总成交额9.2%，游资资金净流入386.11万 元，占总成交额3.81%，散户资金净流入547.79万元，占总成交额5.4%。 证券之星消息，截至2025年12月5日收盘，美好医疗(301363)报收于21.42元，下跌0.46%，换手率 1.27%，成交量4.75万手，成交额1.01亿元。 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 该股最近90天内共有13家机构给出评级，买入评级11家，增持评级2家；过去90天内机构目标均 ...

证券之星消息，截至2025年12月4日收盘，美好医疗(301363)报收于21.52元，上涨1.03%，换手率 1.68%，成交量6.27万手，成交额1.34亿元。 12月4日的资金流向数据方面，主力资金净流入531.81万元，占总成交额3.98%，游资资金净流出457.73 万元，占总成交额3.43%，散户资金净流出74.08万元，占总成交额0.55%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-04 | 21.52 | 1.03% | 531.81万 | 3.98% | -457.73万 | -3.43% | -74.08万 | -0.55% | | 2025-12-03 | | 21.30 0.42% | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | | 21.2 ...

近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 21.30 0.42% | | 2118.31万 | 13.39% | 1423.55万 | 9.00% | -3541.86万 | -22.38% | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 | -0.19% | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 | 0.66% | -121.73万 | -1.81% | 164.01万 | 2.43% | -42.29万 | -0.63% | | 2025-11-27 | 21.09 | 0 ...

Group 1: Conferences and Events - The "2025 Brain-Computer Interface Conference" will be held in Shanghai from December 4 to 5, featuring the first large-scale domestic multi-track brain-computer interface competition and a developer conference [2] - The "2025 Intelligent Connection·Future" International Conference will take place in Hangzhou on December 11 to 12, focusing on the cutting-edge technology and application hotspots of brain-computer intelligence [2] - The "2025 Shenzhen Brain Expo" will occur in Shenzhen on December 28 to 29, promoting a new pattern of brain-computer interface development through three major interaction themes [2] Group 2: Policy Support - Brain-computer interfaces have been elevated to a national strategy and are included in the "14th Five-Year Plan" [3] - The Ministry of Industry and Information Technology and other departments issued implementation opinions aiming for breakthroughs in key technologies by 2027 and significant improvements in innovation capabilities by 2030 [3] - Local policies supporting brain-computer interfaces have emerged in various regions, including Shanghai and Beijing, with specific targets for clinical trials and application scenarios [3] Group 3: Investment and Financing - As of November, there have been 28 financing events in the brain-computer interface sector in China, with total financing exceeding 5 billion yuan, including a record 350 million yuan financing by Ladder Medical [4] - Capital is accelerating towards the brain-computer interface field due to policy encouragement [4] Group 4: Market Potential - The global market for brain-computer interfaces in medical applications is projected to reach 40 billion USD by 2030 and exceed 145 billion USD by 2040 according to McKinsey [5] Group 5: Company Developments - Sixteen brain-computer interface concept stocks have received institutional research, with companies like Xiangyu Medical and Lepu Medical actively engaging in the sector [7] - Companies are focusing on integrating brain-computer interface technology into their products, with significant R&D investments directed towards this area [7]

Core Insights - The brain-computer interface (BCI) has been elevated to a "national strategy" and is recognized as one of the six future industries requiring forward-looking layout, as stated in the 14th Five-Year Plan [2] - Multiple large-scale BCI conferences are scheduled in December 2025 across various cities, showcasing significant advancements and investment opportunities in the sector [1] Industry Developments - Various local governments, including Shanghai, Beijing, Sichuan, Zhejiang, and Jiangxi, have introduced supportive policies for BCI development [3] - Shanghai's action plan aims for breakthroughs in semi-invasive BCI products by 2027, while Beijing's plan focuses on achieving major original results in key technologies by the same year [3] Clinical Application and Regulation - The National Medical Insurance Administration has opened a "green channel" for BCI and other innovative medical products to facilitate their approval [4] - The National Medical Products Administration has included a wireless implanted BCI system in its special review process for innovative medical devices [4] Investment Trends - Capital is rapidly flowing into the BCI sector, with 28 financing rounds completed in 2023, totaling over 5 billion yuan, and a record 350 million yuan raised by Ladder Medical [5] - The global market for BCIs in medical applications is projected to reach $40 billion by 2030 and exceed $145 billion by 2040 [5] Market Performance - BCI-related stocks have shown remarkable performance in 2023, with companies like Century Huatong rising over 250% and others doubling in value [6] - 16 BCI concept stocks have undergone institutional research, indicating strong interest from investors [6] Company Insights - Xiangyu Medical reported that 60%-70% of its R&D investment is related to BCI technology [7] - Lepu Medical plans to deepen its brainwave collection technology and integrate it with neural stimulation and intelligent algorithms [7] - Meihua Medical is collaborating with BCI clients to facilitate efficient commercialization from laboratory research to mass production [7]

证券之星消息，截至2025年12月2日收盘，美好医疗(301363)报收于21.21元，上涨0.09%，换手率 0.72%，成交量2.7万手，成交额5676.04万元。 12月2日的资金流向数据方面，主力资金净流出200.72万元，占总成交额3.54%，游资资金净流入260.69 万元，占总成交额4.59%，散户资金净流出59.96万元，占总成交额1.06%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-02 | 21.21 0.09% | | -200.72万 | -3.54% | 260.69万 | 4.59% | -59.96万 | -1.06% | | 2025-12-01 | 21.19 -0.19% | | -232.84万 | -3.84% | -20.18万 | -0.33% | 253.02万 | 4.17% | | 2025-11-28 | 21.23 0 ...

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]